Using Kaplan–Meier analysis, the mRNA expression values of three of these genes (HIF1A, TRIM22, and PARP9 mRNA) showed prolonged improvements in survival times for patients expressing high levels of these three genes along with high methylation load across all the GBM patients. This evidence concerns the gene TRIM22 and glioblastoma.